|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
DE602004028930D1
(de)
*
|
2003-04-29 |
2010-10-14 |
Avi Biopharma Inc |
Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
AU2005208710A1
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
*
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
EP2206781B1
(en)
|
2004-06-28 |
2015-12-02 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US8129352B2
(en)
*
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
EP1855694B1
(en)
*
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
US8168181B2
(en)
*
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
EP2438962A3
(en)
|
2006-02-13 |
2012-07-18 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
EP2235034B1
(en)
*
|
2007-12-28 |
2016-11-23 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
*
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
*
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
EP2283029A1
(en)
|
2008-06-04 |
2011-02-16 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
*
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP2762567B1
(en)
*
|
2008-10-24 |
2016-07-13 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for DMD
|
|
EP2376633A1
(en)
*
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
WO2010123369A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
PL2499249T3
(pl)
|
2009-11-12 |
2019-03-29 |
Univ Western Australia |
Cząsteczki antysensowne i sposoby leczenia patologii
|
|
CN102712928B
(zh)
|
2009-11-13 |
2017-08-04 |
萨雷普塔治疗公司 |
反义抗病毒化合物及治疗流感病毒感染的方法
|
|
JP5677454B2
(ja)
*
|
2009-12-11 |
2015-02-25 |
グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー |
細胞内ターゲット結合用二座ペプチドバインダー
|
|
WO2011127210A1
(en)
*
|
2010-04-06 |
2011-10-13 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
KR101829644B1
(ko)
|
2010-05-28 |
2018-02-19 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
KR101900770B1
(ko)
*
|
2010-07-19 |
2018-09-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
CN103619356B
(zh)
*
|
2011-05-05 |
2017-09-12 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
EP2750715B1
(en)
|
2011-08-30 |
2018-10-31 |
The Regents of The University of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
EP2751128B1
(en)
|
2011-08-30 |
2021-03-03 |
United Kingdom Research and Innovation |
Cell-penetrating peptides having a central hydrophobic domain
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
ES2535654T3
(es)
*
|
2011-10-13 |
2015-05-13 |
Association Institut De Myologie |
ADN triciclo-fosforotioato
|
|
US9066967B2
(en)
|
2011-12-08 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human LMNA
|
|
CN118581086A
(zh)
*
|
2012-01-27 |
2024-09-03 |
比奥马林技术公司 |
用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
KR20150030205A
(ko)
*
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
EP2850185A4
(en)
*
|
2012-05-16 |
2015-12-30 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
KR101329411B1
(ko)
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
EP2875051B1
(en)
|
2012-07-19 |
2019-02-20 |
Daiichi Sankyo Company, Limited |
Anti-siglec-15 antibodies
|
|
CN116271053A
(zh)
|
2012-08-13 |
2023-06-23 |
洛克菲勒大学 |
治疗和诊断黑素瘤
|
|
JP6404219B2
(ja)
|
2012-09-25 |
2018-10-10 |
ジェンザイム・コーポレーション |
筋強直性ジストロフィーを治療するためのペプチド結合モルホリノアンチセンスオリゴヌクレオチド
|
|
ES2724853T3
(es)
|
2012-11-15 |
2019-09-16 |
Roche Innovation Ct Copenhagen As |
Conjugados de oligonucleótidos
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
BR122020016865B1
(pt)
|
2013-03-14 |
2022-12-27 |
Sarepta Therapeutics, Inc. |
Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
|
|
BR112015022998A2
(pt)
|
2013-03-15 |
2017-11-14 |
Sarepta Therapeutics Inc |
composições melhoradas para o tratamento de distrofia muscular
|
|
EP3065783A4
(en)
|
2013-11-06 |
2017-06-21 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
JP6901966B2
(ja)
|
2014-05-16 |
2021-07-14 |
オレゴン ステート ユニバーシティ |
アンチセンス抗菌化合物および方法
|
|
JP6687542B2
(ja)
|
2014-05-19 |
2020-04-22 |
オレゴン ステート ユニバーシティ |
アンチセンス抗菌化合物および方法
|
|
CA2949104C
(en)
|
2014-05-23 |
2023-09-26 |
Genzyme Corporation |
Multiple oligonucleotide moieties on peptide carrier
|
|
EP3795687A1
(en)
|
2014-05-23 |
2021-03-24 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
HK1246303A1
(zh)
*
|
2014-12-31 |
2018-09-07 |
Oregon State University |
反义抗菌化合物和方法
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
BR112018007066A2
(pt)
*
|
2015-10-09 |
2018-10-23 |
Sarepta Therapeutics Inc |
composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
|
|
EP3394261A4
(en)
|
2015-12-23 |
2019-11-27 |
Oregon State University |
ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
|
|
EP3394262B1
(en)
*
|
2015-12-23 |
2024-08-28 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
KR102329187B1
(ko)
|
2016-04-29 |
2021-11-22 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
인간 lmna를 표적화하는 올리고뉴클레오타이드 유사체
|
|
MY205600A
(en)
|
2016-12-19 |
2024-10-29 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
US10800817B2
(en)
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
PL3554552T3
(pl)
|
2016-12-19 |
2022-11-21 |
Sarepta Therapeutics, Inc. |
Koniugaty oligomerów do pomijania egzonów dla dystrofii mięśniowej
|
|
SMT202200366T1
(it)
|
2016-12-19 |
2022-11-18 |
Sarepta Therapeutics Inc |
Coniugati di oligomeri per salto di esone per distrofia muscolare
|
|
SG11201906200WA
(en)
|
2017-01-06 |
2019-08-27 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
GB201711809D0
(en)
*
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3687547A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3697422A4
(en)
|
2017-10-17 |
2021-08-11 |
Sarepta Therapeutics, Inc. |
CELL PENETRATION PEPTIDES FOR ANTISENS ADMINISTRATION
|
|
EP3713575A4
(en)
|
2017-11-21 |
2021-08-25 |
Rgenix, Inc. |
POLYMORPHS AND THEIR USES
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
US11987647B2
(en)
|
2018-05-09 |
2024-05-21 |
Ohio State Innovation Foundation |
Cyclic cell-penetrating peptides with one or more hydrophobic residues
|
|
EP4219717A3
(en)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
AU2019314538B2
(en)
*
|
2018-08-02 |
2025-03-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
BR112021010982A2
(pt)
|
2018-12-07 |
2021-08-31 |
Oxford University Innovation Limited |
Ligantes
|
|
IL318474A
(en)
|
2018-12-13 |
2025-03-01 |
Sarepta Therapeutics Inc |
Axon-skipping oligomer complexes for muscular dystrophy
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
EP3955966A1
(en)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
EP4073025B1
(en)
|
2019-12-13 |
2024-03-27 |
Inspirna, Inc. |
Metal salts and uses thereof
|
|
CA3165961A1
(en)
|
2019-12-26 |
2021-07-01 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid that induces skipping of exon 50
|
|
CA3173049A1
(en)
|
2020-02-28 |
2021-09-02 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid inducing skipping of exon 51
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
JP2024501800A
(ja)
|
2020-12-23 |
2024-01-16 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療するためのエクソンスキッピングオリゴヌクレオチドコンジュゲートを含む組成物
|
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
CA3224782A1
(en)
|
2021-06-23 |
2022-12-29 |
Nippon Shinyaku Co., Ltd. |
Combination of antisense oligomers
|
|
EP4368186A4
(en)
|
2021-07-08 |
2025-06-25 |
Nippon Shinyaku Co., Ltd. |
NEPHROTOXICITY REDUCING AGENT
|
|
IL310001A
(en)
|
2021-07-08 |
2024-03-01 |
Nippon Shinyaku Co Ltd |
Precipitation suppressing agent
|
|
US20240285547A1
(en)
|
2021-07-08 |
2024-08-29 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023034515A2
(en)
*
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
US20250195667A1
(en)
|
2022-03-17 |
2025-06-19 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
CN119183457A
(zh)
|
2022-04-15 |
2024-12-24 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物和制剂
|
|
WO2023205451A1
(en)
|
2022-04-22 |
2023-10-26 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
WO2024097822A1
(en)
|
2022-11-02 |
2024-05-10 |
Sarepta Therapeutics, Inc. |
Formulation of an antisense oligomer conjugate
|
|
EP4634373A1
(en)
|
2022-12-16 |
2025-10-22 |
University of Rochester |
Repairment of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|